{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T05:42:03Z","timestamp":1792474923634,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003452","name":"Innovation and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007156","name":"Innovation and Technology Commission - Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007156","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ejmech.2025.117952","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T19:39:48Z","timestamp":1751917188000},"page":"117952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Structure-activity relationship studies of thiazole-based derivatives leading to the identification of novel and potent SARS-CoV-2 main protease inhibitors"],"prefix":"10.1016","volume":"297","author":[{"given":"Weile","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai-Po","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siu-Lun","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheung-Hin","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4984-7109","authenticated-orcid":false,"given":"Kwok-Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117952_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.552909","article-title":"Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza A respiratory viruses","volume":"11","author":"Abdelrahman","year":"2020","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.ejmech.2025.117952_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127377","article-title":"The SARS-CoV-2 main protease as drug target","volume":"30","author":"Ullrich","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"9","key":"10.1016\/j.ejmech.2025.117952_bib6","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1021\/acs.jmedchem.9b01828","article-title":"alpha-Ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication: structure-based design, synthesis, and activity assessment","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2025.117952_bib7","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1111\/febs.12936","article-title":"From SARS to MERS: crystallographic studies on coronaviral proteases enable antiviral drug design","volume":"281","author":"Hilgenfeld","year":"2014","journal-title":"FEBS J."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117952_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.virusres.2007.02.015","article-title":"Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery","volume":"133","author":"Grum-Tokars","year":"2008","journal-title":"Virus Res."},{"issue":"23","key":"10.1016\/j.ejmech.2025.117952_bib9","doi-asserted-by":"crossref","first-page":"13190","DOI":"10.1073\/pnas.1835675100","article-title":"The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor","volume":"100","author":"Yang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117952_bib10","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1021\/acs.jcim.1c00449","article-title":"Dynamic profiling of beta-Coronavirus 3CL M(pro) protease ligand-binding sites","volume":"61","author":"Cho","year":"2021","journal-title":"J. Chem. Inf. Model."},{"issue":"13","key":"10.1016\/j.ejmech.2025.117952_bib11","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/emboj\/cdf327","article-title":"Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain","volume":"21","author":"Anand","year":"2002","journal-title":"The EMBO journal"},{"issue":"46","key":"10.1016\/j.ejmech.2025.117952_bib12","doi-asserted-by":"crossref","first-page":"12997","DOI":"10.1073\/pnas.1601327113","article-title":"SARS-CoV 3CL protease cleaves its C-terminal autoprocessing site by novel subsite cooperativity","volume":"113","author":"Muramatsu","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7811","key":"10.1016\/j.ejmech.2025.117952_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.ejmech.2025.117952_bib14","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J. Med. Chem."},{"issue":"42","key":"10.1016\/j.ejmech.2025.117952_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd4596","article-title":"Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti-COVID-19 drug design","volume":"6","author":"Rut","year":"2020","journal-title":"Sci. Adv."},{"issue":"7835","key":"10.1016\/j.ejmech.2025.117952_bib16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-020-2601-5","article-title":"Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity","volume":"587","author":"Shin","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ejmech.2025.117952_bib17","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/s41598-022-05424-3","article-title":"Pro108Ser mutation of SARS-CoV-2 3CL(pro) reduces the enzyme activity and ameliorates the clinical severity of COVID-19","volume":"12","author":"Abe","year":"2022","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117952_bib18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.drudis.2018.01.028","article-title":"Influenza A virus polymerase: an attractive target for next-generation anti-influenza therapeutics","volume":"23","author":"Zhou","year":"2018","journal-title":"Drug Discov. Today"},{"issue":"11","key":"10.1016\/j.ejmech.2025.117952_bib19","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1111\/cas.14618","article-title":"RNA-dependent RNA polymerase, RdRP, a promising therapeutic target for cancer and potentially COVID-19","volume":"111","author":"Machitani","year":"2020","journal-title":"Cancer Sci."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117952_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139001","article-title":"Structural analysis of monomeric RNA-dependent polymerases: evolutionary and therapeutic implications","volume":"10","author":"Jacome","year":"2015","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/j.ejmech.2025.117952_bib21","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1128\/JVI.00080-16","article-title":"Homology-based identification of a mutation in the coronavirus RNA-dependent RNA polymerase that confers resistance to multiple mutagens","volume":"90","author":"Sexton","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.ejmech.2025.117952_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26195795","article-title":"Discovery, development, and patent trends on Molnupiravir: a prospective oral treatment for COVID-19","volume":"26","author":"Imran","year":"2021","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.ejmech.2025.117952_bib23","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.117952_bib24","article-title":"Targeting SARS-CoV-2 proteases and polymerase for COVID-19 treatment: state of the art and future opportunities","author":"Cannalire","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117952_bib25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.bjp.0707373","article-title":"Origin and evolution of high throughput screening","volume":"152","author":"Pereira","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.ejmech.2025.117952_bib26","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/cmdc.202000223","article-title":"Drug development and medicinal chemistry efforts toward SARS-coronavirus and Covid-19 therapeutics","volume":"15","author":"Ghosh","year":"2020","journal-title":"ChemMedChem"},{"issue":"20","key":"10.1016\/j.ejmech.2025.117952_bib27","doi-asserted-by":"crossref","first-page":"5684","DOI":"10.1016\/j.bmcl.2008.08.082","article-title":"Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors","volume":"18","author":"Ghosh","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"6557","key":"10.1016\/j.ejmech.2025.117952_bib28","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1126\/science.abg5827","article-title":"Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2","volume":"373","author":"Drayman","year":"2021","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.ejmech.2025.117952_bib29","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"issue":"6489","key":"10.1016\/j.ejmech.2025.117952_bib30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117952_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112711","article-title":"The development of coronavirus 3C-Like protease (3CL(pro)) inhibitors from 2010 to 2020","volume":"206","author":"Liu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117952_bib32","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.1021\/acs.jmedchem.4c02561","article-title":"Discovery of Nirmatrelvir (PF-07321332): a potent, orally active inhibitor of the severe acute respiratory syndrome Coronavirus 2 (SARS CoV-2) main protease","volume":"68","author":"Tuttle","year":"2025","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117952_bib33","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jpha.2022.10.005","article-title":"Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection","volume":"13","author":"Chen","year":"2023","journal-title":"J. Pharm. Anal."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117952_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac389","article-title":"Prevalence of medical contraindications to Nirmatrelvir\/Ritonavir in a cohort of hospitalized and nonhospitalized patients with COVID-19","volume":"9","author":"Lim","year":"2022","journal-title":"Open Forum Infect. Dis."},{"issue":"8","key":"10.1016\/j.ejmech.2025.117952_bib35","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1021\/jm061425k","article-title":"Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters","volume":"50","author":"Zhang","year":"2007","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117952_bib36","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/s41467-021-22362-2","article-title":"Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors","volume":"12","author":"Iketani","year":"2021","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.ejmech.2025.117952_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200635","article-title":"A critical study on acylating and covalent reversible fragment inhibitors of SARS-CoV-2 main protease targeting the S1 site with pyridine","volume":"18","author":"Wamser","year":"2023","journal-title":"ChemMedChem"},{"issue":"19","key":"10.1016\/j.ejmech.2025.117952_bib38","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1021\/bi0101190","article-title":"Kinetic analysis of matrix metalloproteinase activity using fluorogenic triple-helical substrates","volume":"40","author":"Lauer-Fields","year":"2001","journal-title":"Biochemistry"},{"issue":"10","key":"10.1016\/j.ejmech.2025.117952_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0030324","article-title":"Design of wide-spectrum inhibitors targeting coronavirus main proteases","volume":"3","author":"Yang","year":"2005","journal-title":"PLoS Biol."},{"key":"10.1016\/j.ejmech.2025.117952_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105455","article-title":"The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus","volume":"117","author":"Qiao","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.117952_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115721","article-title":"Discovery of highly potent covalent SARS-CoV-2 3CL(pro) inhibitors bearing 2-sulfoxyl-1,3,4-oxadiazole scaffold for combating COVID-19","volume":"260","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117952_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115021","article-title":"Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors","volume":"247","author":"Previti","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"1\u20132","key":"10.1016\/j.ejmech.2025.117952_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mam.2008.08.006","article-title":"Glutathione: overview of its protective roles, measurement, and biosynthesis","volume":"30","author":"Forman","year":"2009","journal-title":"Mol. Aspect. Med."},{"issue":"33","key":"10.1016\/j.ejmech.2025.117952_bib44","doi-asserted-by":"crossref","first-page":"17205","DOI":"10.1016\/S0021-9258(19)77815-6","article-title":"Glutathione metabolism and its selective modification","volume":"263","author":"Meister","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.117952_bib45","series-title":"SARS-CoV-2: Methods and Protocols","first-page":"379","article-title":"Cytopathic effect (CPECytopathic effects (CPE))-based drug screening AssayDrug screening assay for SARS-CoV-2","author":"Ng","year":"2022"},{"key":"10.1016\/j.ejmech.2025.117952_bib46","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ejmech.2014.07.025","article-title":"Multi-dimensional target profiling of N,4-diaryl-1,3-thiazole-2-amines as potent inhibitors of eicosanoid metabolism","volume":"84","author":"Rodl","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117952_bib47","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejmech.2012.01.008","article-title":"Design, synthesis of some new (2-aminothiazol-4-yl)methylester derivatives as possible antimicrobial and antitubercular agents","volume":"49","author":"Karuvalam","year":"2012","journal-title":"Eur. J. Med. Chem."},{"issue":"Pt 4","key":"10.1016\/j.ejmech.2025.117952_bib48","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1107\/S0907444910048675","article-title":"iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM","volume":"67","author":"Battye","year":"2011","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"7","key":"10.1016\/j.ejmech.2025.117952_bib49","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1107\/S0907444913000061","article-title":"How good are my data and what is the resolution?","volume":"69","author":"Evans","year":"2013","journal-title":"Acta Crystallogr. D"},{"issue":"Pt 2","key":"10.1016\/j.ejmech.2025.117952_bib50","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1107\/S2059798317016035","article-title":"CCP4i2: the new graphical user interface to the CCP4 program suite","volume":"74","author":"Potterton","year":"2018","journal-title":"Acta crystallographica Section D, Structural biology"},{"issue":"Pt 4","key":"10.1016\/j.ejmech.2025.117952_bib51","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117952_bib52","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15930-z","article-title":"Hepatitis C virus NS3\/4A inhibitors and other drug-like compounds as covalent binders of SARS-CoV-2 main protease","volume":"12","author":"Andi","year":"2022","journal-title":"Sci. Rep."},{"issue":"Pt 12 Pt 1","key":"10.1016\/j.ejmech.2025.117952_bib53","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1107\/S0907444904019158","article-title":"Coot: model-building tools for molecular graphics","volume":"60","author":"Emsley","year":"2004","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"Pt 12 Pt 1","key":"10.1016\/j.ejmech.2025.117952_bib54","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1107\/S0907444904023510","article-title":"REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use","volume":"60","author":"Vagin","year":"2004","journal-title":"Acta Crystallogr D Biol Crystallogr"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425007172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:59:14Z","timestamp":1776920354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425007172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":51,"alternative-id":["S0223523425007172"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117952","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-activity relationship studies of thiazole-based derivatives leading to the identification of novel and potent SARS-CoV-2 main protease inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117952","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117952"}}